Windlas Biotech Limited announced the recommendation of a dividend for the financial year ended March 31, 2026, following a board meeting held on May 21, 2026. The company simultaneously disclosed its financial results for the period, marking another year of consistent shareholder returns for the Dehradun-based pharmaceutical contract development and manufacturing organisation (CDMO).

Dividend Details and Yield

While the exact per-share quantum for FY2026 is pending formal disclosure in exchange filings, the announcement confirms the board has recommended a final dividend. At the current market price of ₹782, even a payout in line with the prior year's ₹4 per share would translate to a dividend yield of approximately 0.51%. Investors will need to monitor the record date announcement to confirm eligibility for the payout.

Dividend History and Trend

Windlas Biotech has maintained an unbroken dividend payout record since FY2022, reflecting a steady upward trajectory in shareholder distributions:

The consistent and growing payout pattern over three disclosed cycles underlines management's commitment to returning capital to shareholders even as the company invests in expanding its CDMO capabilities.

Valuation and Market Context

Windlas Biotech currently trades at a price-to-earnings (PE) ratio of 25.24, which is precisely in line with the sector PE of 25.24, suggesting the stock is fairly valued relative to its pharmaceutical peers at present levels. The stock closed at ₹782 on May 21, 2026, down 2.01% on the day, reflecting broader market sentiment rather than any company-specific negative development.

The 52-week range spans from a low of ₹697.40 recorded on March 16, 2026 to a high of ₹1,097.90 reached on August 19, 2025. The current price of ₹782 sits approximately 28.7% below its 52-week peak but 12.1% above its 52-week trough, positioning the stock in the lower half of its annual trading band. The market capitalisation stands at ₹1,650.51 Cr.

Delivery Data and Investor Participation

On the day of the announcement, delivery volume as a percentage of total traded volume stood at 57.5%, against a total volume of 58,538 shares. A delivery percentage above 50% generally indicates that a meaningful proportion of trades resulted in actual share transfers rather than intraday activity, pointing to genuine investor interest on a day marked by the board outcome. Daily volatility is recorded at 2.53%, which is moderate for a small-cap pharmaceutical counter.

Company Background

Windlas Biotech is one of India's top pharmaceutical CDMO players, specialising in oral solid dosage forms. The company serves several major domestic formulation companies and has been expanding its product development services segment. Its asset-light CDMO model has historically supported cash generation sufficient to sustain dividend payouts alongside capital expenditure.

Investors should watch for the formal intimation of the dividend amount and the record date, both of which will be filed separately with NSE following the board's recommendation disclosed on May 21, 2026.